Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major Clinical research trials and Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major. Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major clinical trial. Participants oftentimes recieve the most expert healthcare available for their Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.

Home > "P" Clinical Trials Conditions > Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major

Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major



Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major

For Condition: Thalassemia Major
Status: Terminated
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ,
Synopsis: OBJECTIVES: I. Determine the safety and efficacy of azacitidine and phenylbutyrate in treatment of patients with thalassemia major.
Details: PROTOCOL OUTLINE: Patients receive azacitidine IV continuously on days 1-4 and oral phenylbutyrate three times a day on days 14-42. Bone marrow needle aspiration is performed on days 6, 14, and 42 to assess disease response to treatment. If no response on day 42, a second course of azacitidine and phenylbutyrate begins 7 days later. Patients are followed weekly for 3 months and then monthly thereafter.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of thalassemia major Progressive disease defined as: Increasing transfusion requirement or difficulty in maintenance of hemoglobin levels greater than 7 g/dL as a consequence of autologous or allogeneic antibodies OR Increasing extramedullary hematopoiesis causing compression phenomena OR Disease with complications of iron overload despite traditional transfusion and iron chelation therapy (e.g., heart failure, decreased cardiac ejection fraction, endocrinopathy, or evidence of progressive liver dysfunction) Standard transfusion therapy or iron chelation therapy must be contraindicated --Prior/Concurrent Therapy-- See Disease Characteristics --Patient Characteristics-- Performance status: ECOG 0-2 Life expectancy: Greater than 10 days Not moribund Hematopoietic: See Disease Characteristics Hepatic: See Disease Characteristics AST or ALT no greater than 3 times upper limit of normal (ULN) Bilirubin no greater than 1.5 times ULN (unless due to hemolysis or Gilbert's disease) Albumin at least 3 g/dL No severe concurrent hepatic disease Renal: Creatinine no greater than 2 mg/dL Creatinine clearance at least 60 mL/min No severe concurrent renal disease Cardiovascular: See Disease Characteristics No New York Heart Association class III or IV Other: Not pregnant or nursing No severe concurrent metabolic disease No severe sepsis or septic shock No concurrent altered mental status or seizure disorder No concurrent myelodysplastic syndrome or leukemia
Total Enrollment: 24

Location and Contact Information:

Overall Study Official:
GriffinRodgers,  Study Chair,  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Clinical Hematology Branch
Bethesda,  Maryland,  20892
United States
 


Additional Information:
Study ID Numbers:  199/15578;  NIDDK-00-DK-0166,NCI-1311
Study Start Date: November 2000
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00007072

Other Thalassemia Major Studies:
1. Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders

2. Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major

3. Stem Cell Transplantation after Reduced-Dose Chemotherapy for Patients with Sickle Cell Disease or Thalassemia

4. Diagnostic Pilot Study of Dual Energy Absorptiometry in the Detection of Osteopenia or Osteoporosis in Patients With Thalassemia Major

5. Stem Cell Transplantation (SCT) for Genetic Diseases

Related Studies:

Other Thalassemia Major Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials

Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major
Modify your Search

  Other Thalassemia Major Clinical Trials
  Other Maryland Clinical Trials
  Other Bethesda Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103